688197 首药控股-U
已收盘 09-16 15:00:01
资讯
新帖
简况
每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市
证券之星 · 08-30
每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市
首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%
证券之星 · 08-26
首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%
每周股票复盘：首药控股（688197）变更持续督导保荐代表人
证券之星 · 08-09
每周股票复盘：首药控股（688197）变更持续督导保荐代表人
首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%
证券之星 · 08-04
首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%
每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件
证券之星 · 07-19
每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件
首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书
智通财经 · 07-16
首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书
每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务
证券之星 · 07-12
每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务
异动快报：首药控股-U（688197）7月6日10点14分触及涨停板
证券之星 · 07-06
异动快报：首药控股-U（688197）7月6日10点14分触及涨停板
每周股票复盘：首药控股（688197）召开2025年年度股东会
证券之星 · 06-28
每周股票复盘：首药控股（688197）召开2025年年度股东会
首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%
证券之星 · 06-26
首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%
首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市
智通财经 · 06-11
首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
证券之星 · 05-17
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
【机构调研记录】金鹰基金调研首药控股
证券之星 · 05-15
【机构调研记录】金鹰基金调研首药控股
【机构调研记录】东方基金调研达瑞电子、首药控股
证券之星 · 05-15
【机构调研记录】东方基金调研达瑞电子、首药控股
首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与
证券之星 · 05-14
首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与
首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%
证券之星 · 05-06
首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%
每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄
证券之星 · 05-02
每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄
首药控股（688197）2026年一季报简析：营收上升亏损收窄
证券之星 · 04-19
首药控股（688197）2026年一季报简析：营收上升亏损收窄
每周股票复盘：首药控股（688197）股东户数增11.6%
证券之星 · 04-19
每周股票复盘：首药控股（688197）股东户数增11.6%
首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%
证券之星 · 04-17
首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%
加载更多
公司概况
公司名称：
首药控股(北京)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-23
主营业务：
首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是SY-707（康特替尼颗粒）。
发行价格：
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股-U","latestPrice":32.75,"timestamp":1789542001000,"preClose":32.06,"halted":0,"volume":1674112,"delay":0,"changeRate":0.0215,"floatShares":64004900,"shares":149000000,"eps":-0.5751,"marketStatus":"已收盘","change":0.69,"latestTime":"09-16 15:00:01","open":31.98,"high":33.08,"low":31.54,"amount":54235800,"amplitude":0.048,"askPrice":32.75,"askSize":54,"bidPrice":32.74,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.5751,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":5,"adr":0,"adjPreClose":32.06,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":35.27,"lowLimit":28.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":7.87,"roa":"--","roe":"--","epsLYR":-0.87,"committee":-0.406452,"marketValue":4871000000,"turnoverRate":0.0262,"status":0,"afterMarket":{"amount":0,"volume":0,"close":32.75,"buyVolume":0,"sellVolume":0,"time":1789544037746,"indexStatus":"已收盘 09-16 15:30:00","preClose":32.06},"floatMarketCap":2096000000},"requestUrl":"/m/hq/s/688197","defaultTab":"news","newsList":[{"id":"2663004513","title":"每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004513","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663004513?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:13","pubTimestamp":1788055988,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，首药控股报收于34.94元，较上周的37.71元下跌7.35%。本周，首药控股8月24日盘中最高价报38.45元。股本股东变化截至2026年6月30日，公司股东户数为5917.0户，较3月31日增加328.0户，增幅5.87%。户均持股数量由上期的2.66万股降至2.51万股，户均持股市值为83.97万元。公司持续推进“提质增效重回报”行动方案，进入研发与商业化协同推进新阶段，经营亏损大幅收窄，财务结构稳健，募集资金使用规范。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","688197","06978","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662183718","title":"首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662183718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662183718?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:52","pubTimestamp":1787741566,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，首药控股报收于35.22元，较前一交易日下跌1.1%，最新总市值为52.38亿元。首药控股（北京）股份有限公司于近日披露《关于签订〈施工总承包合同〉暨对外投资的进展公告》。公告显示，公司于2026年8月25日与杭萧钢构（河北）建设有限公司正式签订《施工总承包合同》，合同金额为人民币38,916.87万元（含税），用于建设“首药控股新药研发与产业化基地项目”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600042651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673675","title":"每周股票复盘：首药控股（688197）变更持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673675?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:49","pubTimestamp":1786214949,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，首药控股报收于36.2元，较上周的32.26元上涨12.21%。本周，首药控股8月7日盘中最高价报36.25元。本周关注点公司公告汇总：首药控股变更持续督导保荐代表人，王辉接替杨慧泽履行督导职责。公司公告汇总首药控股（北京）股份有限公司发布公告，因原持续督导保荐代表人杨慧泽先生工作调动，中信建投证券指派王辉先生接替其职务，继续履行公司首次公开发行股票并在科创板上市项目的持续督导职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552288","title":"首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552288?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:33","pubTimestamp":1785853993,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，首药控股报收于32.14元，较前一交易日上涨1.07%，最新总市值为47.8亿元。该股当日开盘31.8元，最高33.18元，最低31.8元，成交额达6516.55万元，换手率为3.14%。近日，首药控股（北京）股份有限公司发布公告称，因原持续督导保荐代表人杨慧泽先生工作调动，中信建投证券指派王辉先生接替其职务，继续履行公司首次公开发行股票并在科创板上市项目的持续督导职责。变更后，持续督导保荐代表人为王辉先生和李彦芝女士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230754","title":"每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230754","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652230754?lang=zh_cn&edition=full","pubTime":"2026-07-19 03:12","pubTimestamp":1784401931,"startTime":"0","endTime":"0","summary":"本周，首药控股7月15日盘中最高价报45.95元。本周关注点公司公告汇总：首药控股获第四代ALK抑制剂SY-12321临床试验批准，拟用于解决三代ALK抑制剂耐药问题。公司公告汇总首药控股（北京）股份有限公司自愿披露，公司自主研发的第四代ALK抑制剂SY-12321胶囊获国家药监局核准签发的《药物临床试验批准通知书》，同意开展针对ALK阳性晚期实体瘤的临床试验。目前，国内尚无第四代ALK抑制剂获批上市或进入临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900001098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651141761","title":"首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2651141761","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651141761?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:40","pubTimestamp":1784191217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。SY-12321是公司完全自主研发的化学药品1类创新药，属于第四代小分子ALK抑制剂，是公司完善ALK阳性肿瘤全生命周期治疗布局的重要候选产品，拟重点解决第三代ALK抑制剂治疗后的耐药问题，特别是ALK复合突变介导的耐药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XTN","BK4077","BK4503","BK4585","BK4500","SY","688197","BK4588","BK0239","BK4563","BK4008","ALK","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154311","title":"每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154311","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154311?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:06","pubTimestamp":1783793172,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，首药控股报收于41.09元，较上周的37.5元上涨9.57%。本周，首药控股7月6日盘中最高价报45.0元。本周关注点公司公告汇总：首药控股完成工商变更，新增药品生产、零售、批发及进出口等经营范围。公司公告汇总首药控股（北京）股份有限公司于2026年4月16日和6月26日分别召开第二届董事会第十三次会议及2025年年度股东会，审议通过增加经营范围、修订《公司章程》并办理工商变更登记的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617282","title":"异动快报：首药控股-U（688197）7月6日10点14分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649617282?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304438,"startTime":"0","endTime":"0","summary":"证券之星7月6日盘中消息，10点14分首药控股-U（688197）触及涨停板。其所属行业化学制药目前上涨。领涨股为首药控股。该股为创新药，医药概念热股，当日创新药概念上涨2.82%，医药概念上涨1.87%。7月3日的资金流向数据方面，主力资金净流出3.49万元，占总成交额0.05%，游资资金净流出141.33万元，占总成交额1.87%，散户资金净流入144.82万元，占总成交额1.92%。近5日资金流向一览见下表：首药控股-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600006370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646031658","title":"每周股票复盘：首药控股（688197）召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2646031658","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646031658?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:08","pubTimestamp":1782590892,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，首药控股报收于31.2元，较上周的32.38元下跌3.64%。本周关注点公司公告汇总：首药控股于2026年6月26日召开2025年年度股东会，审议通过多项议案。公司公告汇总北京市竞天公诚律师事务所对首药控股（北京）股份有限公司2025年年度股东会的召集和召开程序、出席会议人员资格、召集人资格、表决程序和表决结果等事项出具法律意见书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646666243","title":"首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646666243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646666243?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:03","pubTimestamp":1782486203,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，首药控股报收于31.2元，较前一交易日下跌3.7%，最新总市值为46.4亿元。该股当日开盘32.0元，最高33.03元，最低31.06元，成交额达4263.09万元，换手率为2.09%。近日，首药控股（北京）股份有限公司发布《2025年年度股东会决议公告》。表决程序符合法律规定，北京市竞天公诚律师事务所出具了法律意见书，确认会议召集、召开及表决合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642583402","title":"首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642583402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642583402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:40","pubTimestamp":1781163619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司近日通过国家药品监督管理局网站获悉，国家药品监督管理局批准公司完全自主研发的1类创新药康特替尼颗粒(CT-707，商品名：首要泽®)上市，该产品单药适用于既往未经过间变性淋巴瘤激酶(ALK)抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4585","IPOS","BK4588","BK4008","ALK","688197","BK4500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636062419","title":"每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062419","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636062419?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:53","pubTimestamp":1778964786,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，首药控股报收于41.74元，较上周的41.64元上涨0.24%。本周，首药控股5月11日盘中最高价报44.92元。答：感谢您对SY-5007的关注。上述结果表明,SY-5007在初治及经治RET融合阳性NSCLC患者中均展现出较高水平的抗肿瘤活性,并具有良好的缓解持续性趋势。在安全性方面,SY-5007整体耐受性良好。截至目前,SY-5007是临床进展最快的完全国产的选择性RET抑制剂之一,进度优势明显。这将进一步拓展SY-5007的适应症人群,扩大其市场空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727990","title":"【机构调研记录】金鹰基金调研首药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635727990?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:02","pubTimestamp":1778803327,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月14日披露的机构调研信息，金鹰基金近期对1家上市公司进行了调研，相关名单如下：1）首药控股 调研纪要：SY-5007在初治和经治RET融合阳性非小细胞肺癌患者中均展现显著抗肿瘤活性，截至2025年4月10日，初治患者ORR为89.3%，经治患者ORR为81.3%，安全性整体可管理。旗下最近一年表现最佳的公募基金产品为金鹰信息产业股票A，最新单位净值为5.43，近一年增长108.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500008481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727630","title":"【机构调研记录】东方基金调研达瑞电子、首药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635727630?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:01","pubTimestamp":1778803278,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月14日披露的机构调研信息，东方基金近期对2家上市公司进行了调研，相关名单如下：1）达瑞电子 调研纪要：公司2025年实现营收318,772.06万元，同比增长24.24%；净利润28,215.41万元，同比增长16.72%。2026年Q1营收80,175.70万元，同比增长21.75%；净利润7,197.77万元，同比增长25.80%。维斯德于2025年7月启动收购，11月完成交割，2026年Q1并表，整合顺利，带来积极业绩贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500008426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","300976","BK0239","BK0214"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745202","title":"首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635745202?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:32","pubTimestamp":1778769147,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月14日首药控股发布公告称公司于2026年5月1日接受机构调研，海通证券、兴业基金、东方基金、中欧基金、景顺长城基金、金鹰基金、中银资管、东方红资管、博裕资本、大家资产、人保养老、华创证券、投资者、广发证券、国金证券、申万宏源、浙商证券、汇添富基金、万家基金、华宝基金参与。在安全性方面,SY-5007整体耐受性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","06837","BK1564","BK0183","BK0070","600837","BK0028","688197","BK1147","BK0012","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189751","title":"首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633189751?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:29","pubTimestamp":1778063354,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，首药控股报收于41.17元，较前一交易日上涨0.78%，最新总市值为61.23亿元。该股当日开盘41.0元，最高41.95元，最低40.37元，成交额达7603.45万元，换手率为2.88%。近日，中信建投证券股份有限公司发布《关于首药控股（北京）股份有限公司2025年度持续督导跟踪报告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623944","title":"每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623944","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632623944?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:09","pubTimestamp":1777673357,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，首药控股报收于40.85元，较上周的38.2元上涨6.94%。本周，首药控股4月30日盘中最高价报41.82元。公司尚未盈利，存在累计未弥补亏损，主要财务数据显示营业收入同比增长119.88%，净亏损收窄。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628754029","title":"首药控股（688197）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2628754029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628754029?lang=zh_cn&edition=full","pubTime":"2026-04-19 06:08","pubTimestamp":1776550104,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期首药控股发布2026年一季报。根据财报显示，首药控股营收上升亏损收窄。其中，净利率-53.9%，同比增97.88%，销售费用、管理费用、财务费用总计519.64万元，三费占营收比18.56%，每股净资产4.47元，同比减12.29%，每股经营性现金流-0.14元，同比增67.57%，每股收益-0.1元，同比增70.59%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-1486.39%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275970","title":"每周股票复盘：首药控股（688197）股东户数增11.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628275970?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:17","pubTimestamp":1776539826,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，首药控股报收于41.3元，较上周的39.39元上涨4.85%。股本股东变化股东户数变动截至2026年3月31日，首药控股股东户数为5589.0户，较2025年12月31日增加581.0户，增幅11.6%。公司公告汇总首药控股（北京）股份有限公司2025年年度报告摘要显示，2025年末资产总额为791,233,717.90元，归属于上市公司股东的净资产为680,178,869.53元。首药控股（北京）股份有限公司2025年度审计报告由天健会计师事务所出具，审计意见为标准无保留意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628202011","title":"首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628202011","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628202011?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:20","pubTimestamp":1776435626,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，首药控股报收于41.3元，较前一交易日下跌1.81%，最新总市值为61.42亿元。该股当日开盘41.73元，最高41.94元，最低40.67元，成交额达6076.8万元，换手率为2.3%。近日，首药控股（北京）股份有限公司披露《2025年年度报告》。公告显示，截至2025年末，公司资产总额为791,233,717.90元，归属于上市公司股东的净资产为680,178,869.53元。2025年公司实现营业收入8,667,574.64元，较2024年增长119.88%。研发投入占营业收入的比例为2,269.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700045992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789566497932,"stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":-0.1451},{"period":"3month","weight":0.0556},{"period":"6month","weight":-0.1861},{"period":"1year","weight":-0.2986},{"period":"ytd","weight":-0.0771}],"compareEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0593},{"period":"6month","weight":-0.0355},{"period":"1year","weight":0.001},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5917人(较上一季度增加5.87%)","perCapita":"10817股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢19层1单元2202-2号","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是SY-707（康特替尼颗粒）。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股-U,688197,首药控股-U股票,首药控股-U股票老虎,首药控股-U股票老虎国际,首药控股-U行情,首药控股-U股票行情,首药控股-U股价,首药控股-U股市,首药控股-U股票价格,首药控股-U股票交易,首药控股-U股票购买,首药控股-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}